Arthritis Research & Therapy最新文献

{"title":"Factors associated with variations in the 6-minute walk distance during the follow-up of patients with systemic sclerosis.","authors":"Marguerite Merger, Jonathan Giovannelli, David Launay, Nicolas Lamblin, Pascal De Groote, Marie Fertin, Jean-François Bervar, Victor Valentin, Vincent Sobanski, Éric Hachulla, Sébastien Sanges","doi":"10.1186/s13075-026-03821-x","DOIUrl":"10.1186/s13075-026-03821-x","url":null,"abstract":"<p><strong>Introduction: </strong>The 6-minute walk distance (6MWD) is commonly used to assess functional capacity in patients with systemic sclerosis (SSc), but its ability to reflect changes in cardiopulmonary status during follow-up remains uncertain. This study aimed to investigate whether variations in the 6MWD accurately mirror changes in organ involvement over time in SSc patients.</p><p><strong>Methods: </strong>We conducted a longitudinal study on a global cohort of 227 consecutive SSc patients, including a subgroup of 88 patients with ILD or PH, over a two-year follow-up period. Statistical analyses were performed to assess associations between variations (Δ) of 6MWD (Δ6MWD) and evolution of organ involvement.</p><p><strong>Results: </strong>The 6MWD varied only mildly during follow-up (mean Δ6MWD - 11.6 ± 67.5 m), including in patients with ILD or PH (mean Δ6MWD - 16 ± 74 m). Significant associations were noted between Δ6MWD and variations of several SSc parameters, mostly with modifications in functional status (changes in ΔBorg (ΔΔBorg) score, p = 0.002; ΔNYHA, p < 10^- 3), PH parameters (Δright atrial area, p = 0.045; persistently elevated Nt-pro-BNP levels, p < 10^- 3), chronotropic function (ΔΔheart rate, p = 0.015; Δinitial heart rate, p = 0.024), musculoskeletal involvement (occurrence of joint symptoms, p = 0.006) and perceived quality of life (ΔHAQ-DI score, p = 0.023). In most cases, the strength of these associations was mild to moderate (R² = 0.53, adjusted R² = 0.36 in multivariate analysis), suggesting the influence of additional factors to explain the majority of Δ6MWD.</p><p><strong>Conclusion: </strong>While it remains valuable as a marker of disability and functioning, the variation in the 6MWD does not seem to be a robust surrogate for modifications in organ involvements of SSc patients.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13281435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147810040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How can innovative trials in juvenile idiopathic arthritis serve the unmet needs of patients?","authors":"Joshua L Bennett, Ethan S Sen, Athimalaipet V Ramanan","doi":"10.1186/s13075-026-03822-w","DOIUrl":"10.1186/s13075-026-03822-w","url":null,"abstract":"<p><p>Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of childhood-onset inflammatory arthritides that remain challenging to treat. An expanding range of biologic and targeted synthetic disease-modifying antirheumatic drugs has improved outcomes, yet major unmet needs persist including predicting treatment response and identifying optimal drug sequences. Traditional frequentist randomised controlled trials (RCTs) are often infeasible in JIA because of small sample sizes and ethical concerns about placebo use in children. Modified RCTs - including randomised withdrawal, placebo-phase, and escape designs - have reduced placebo exposure but have inherent limitations. Here we discuss how innovative trial methodologies may enhance our capacity to generate evidence that can improve outcomes for children and young people with JIA. Adaptive designs, Bayesian methods, sequential multiple assignment randomized trials, and two-stage stop-go designs offer greater flexibility within trials, allowing for study protocols to be adapted based on preliminary data. Insights from multiomic analysis of JIA synovial tissue mean that biologically defined endotypes may fundamentally reshape trial stratification and support biomarker-led precision medicine. Master protocols (basket, umbrella and platform trials) provide opportunities to streamline research by combining data into a single trial. The incorporation of external data can increase statistical power and circumvent challenges in recruiting paediatric controls. Integrating these methodological and biological innovations will be critical for delivering targeted, effective, and age-inclusive therapeutic strategies, ultimately improving outcomes for children and young people living with JIA.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147810091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting osteoarthritis as an inflammatory disease: characterization of synovitis grading and synovial pathotypes in surgical specimens.","authors":"Jacopo Ciaffi, Lorenzo Bianchi, Marco Gambarotti, Alberto Righi, Dilia Giuggioli, Roberto Caporali, Cesare Faldini, Stefano Zaffagnini, Tom W J Huizinga, Francesco Ursini","doi":"10.1186/s13075-026-03819-5","DOIUrl":"10.1186/s13075-026-03819-5","url":null,"abstract":"<p><p>BACKGROUND: Synovial inflammation is increasingly recognized as a relevant component of osteoarthritis (OA), yet its histopathological and immunological features in advanced disease remain incompletely characterized. Whether distinct synovial pathotypes are associated with specific clinical, laboratory, radiographic characteristics, or postoperative outcomes is still unclear. METHODS: In this cross-sectional study, synovial tissue samples from OA patients undergoing hip or knee arthroplasty, or other joint surgery, were analyzed through standardized histology (Krenn score) and semi-quantitative immunohistochemistry (CD3, CD20, CD68, CD138). Pathotypes were categorized as lympho-myeloid, diffuse-myeloid, or pauci-immune. Preoperative demographics, Kellgren–Lawrence radiographic grade, systemic inflammatory markers, and postoperative outcomes were retrieved from clinical records. Comparisons were performed using Kruskal–Wallis and Fisher’s exact tests. A multivariable logistic regression identified predictors of the lympho-myeloid pathotype. RESULTS: Two hundred forty-four samples were analyzed. High-grade synovitis was present in 64.3% of specimens. Pathotype distribution was: 55.3% lympho-myeloid, 11.9% diffuse-myeloid, and 32.8% pauci-immune. Lympho-myeloid tissues displayed the highest inflammatory burden, including elevated Krenn scores and higher systemic inflammatory indices. Pathotype distribution varied across joints, whereas the proportion of high-grade synovitis did not. In multivariable modeling, higher BMI increased the odds of lympho-myeloid pathotype (OR 1.11, 95%CI 1.01–1.22). No associations emerged for inflammatory markers, Kellgren–Lawrence grade or preoperative pain. Postoperative complications were not different across pathotypes. CONCLUSIONS: Advanced OA displays marked synovial heterogeneity, with immune infiltration patterns that parallel systemic inflammatory signatures. Our findings support the concept that synovial pathotypes capture relevant biological variation within OA and may contribute to a more refined framework for disease stratification in future studies. </p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13270653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab.","authors":"Nora Vladimirova, Mikkel Østergaard, Stylianos Georgiadis, Sengül Seven, Jakob M Møller, Bente Jensen, Rene Østgård, Rene Poggenborg, Ole Rintek Madsen, Oliver Hendricks, Lau Brix, Susanne Juhl Pedersen","doi":"10.1186/s13075-026-03816-8","DOIUrl":"10.1186/s13075-026-03816-8","url":null,"abstract":"<p><p>INTRODUCTION: Evidence on treat-to-target strategies in axial spondyloarthritis (axSpA) remains limited. We evaluated 1-year clinical and MRI outcomes of a secukinumab-based dose-escalation treat-to-target strategy aiming for clinical remission (ASDAS < 1.3), and investigated predictors of clinical and MRI-remission. METHODS: TRACE (NCT03639740), was an investigator-initiated, prospective multicentre study including biologic-naïve patients with active axSpA. All patients initiated secukinumab 150mg; those not achieving clinical remission escalated to 300mg; patients still not reaching clinical remission switched to TNF-inhibitors. Sacroiliac joint (SIJ) and spine MRI were performed at baseline and weeks (w) 4, 16, 24, and 56 and centrally scored using SPARCC and CANDEN systems. Predictors of w16 and w56 remission were assessed using multivariable logistic regression. RESULTS: Of 90 included patients, 54 completed w56; 24, 8, and 22 received secukinumab 150mg, 300mg, and TNF-inhibitors, respectively. Overall, 32 patients (59%) achieved w56-clinical-remission. From week 0–56, total MRI-inflammation (SIJ + spine) decreased from mean 39.0 to 6.7, with 43% achieving w56-MRI-remission (SPARCC-SIJ ≤ 1 + CANDEN-spine ≤ 2). Structural lesion remodelling was evident by w4 and sustained through w56 (erosion decreased, fat lesion and backfill increased, new bone formation/ankylosis unchanged). Changes in MRI-inflammation and structural lesions were comparable irrespective of w56-clinical-remission status and treatment at w56. Independent baseline predictors were: Of w16-clinical-remission: ASDAS and BMI; Of w56-clinical-remission: none; Of w16-MRI-remission: female sex, lower MRI-inflammation and higher MRI-erosion score; Of w56-MRI-remission: lower MRI-inflammation and HLA-B27 positivity. CONCLUSION: A 1-year secukinumab-based treat-to-target strategy in axSpA patients provided rapid and sustained clinical improvement, MRI-inflammation reduction and structural remodelling. BMI, sex, HLA-B27 and clinical/MRI disease activity predicted clinical and MRI-remission. </p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13251281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound evaluation of muscle quality in rheumatoid arthritis: a reliability study of the Spanish Ultrasound Muscle Assessment in Rheumatoid Arthritis (SpUMAR) score.","authors":"Juan Molina-Collada, José María Bellón, Boris Blanco-Cáceres, Luis Coronel, Juan José de Agustín, Paula Estrada, Elena Garmendia Sánchez, M Luz García Vivar, Otto Olivas-Vergara, Francisco Gabriel Jiménez Núñez, Lucía Mayordomo, Carmen Moragues, Ana Isabel Rebollo-Giménez, Jacqueline Uson, Esther F Vicente-Rabaneda, Esperanza Naredo","doi":"10.1186/s13075-026-03815-9","DOIUrl":"10.1186/s13075-026-03815-9","url":null,"abstract":"<p><p>OBJECTIVE: This study aimed to 1) develop and test the reliability of a semiquantitative ultrasound score to assess muscle quality in patients with rheumatoid arthritis (RA), and 2) evaluate how incorrect adjustments of ultrasound settings affect muscle quality assessment. METHODS: The Spanish Ultrasound Muscle Assessment in RA (SpUMAR) Score consisted of a semiquantitative 0–3 score based on the degree of loss of the normal muscle ultrasound pattern that was agreed upon by 15 rheumatologists expert in musculoskeletal ultrasound. A total of 164 static ultrasound images of the four bellies of the quadriceps muscle from 57 patients with RA were scored by the experts in two rounds. Additionally, the experts scored 20 ultrasound images that were acquired with incorrectly adjusted settings, which were interposed among the other images. Gwet’s AC2, Fleiss' kappa (κ), Cohen’s κ, applying linear weighting, were used for agreement analysis. RESULTS: The interobserver reliability of SpUMAR was moderate in both rounds (Gwet’s AC2 [95% CI] 0.57 [0.54–0.60] and 0.54 [0.51–0.57], percent agreement 81.76% and 80.28%, respectively). Intraobserver reliability between the two rounds was good (Gwet’s AC2 [95% CI] 0.66 [0.64–0.68]). The agreement between the scores given to the images with incorrect settings and the original scores for those images was poor in both rounds (κ [95% CI]: 0.27 [0.21–0.33] and 0.30 [0.24–0.36], respectively). CONCLUSION: Multiobserver assessment of muscle quality using the SpUMAR score demonstrated acceptable reliability in patients with RA. Incorrect adjustment of ultrasound settings greatly affects muscle quality scoring; therefore, their standardised optimisation is necessary for multicentre studies. </p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13196045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal omega-6 to omega-3 conversion reduces osteoarthritis pain-related behaviors in adult female offspring.","authors":"Arin K Oestreich, Kristin L Lenz, Collin P Murray, Nancy Steward, Sarada Prasad, Sarah K Dunivan, Meredith K Luhmann, Lauryn A Braxton, Farshid Guilak","doi":"10.1186/s13075-026-03817-7","DOIUrl":"10.1186/s13075-026-03817-7","url":null,"abstract":"<p><p>BACKGROUND: A parental high-fat diet (HFD) enriched in inflammatory omega-6 polyunsaturated fatty acids (n-6 PUFAs) increases the severity of post-traumatic osteoarthritis (PTOA) in adult offspring, a risk factor which lacks therapeutic interventions. This study investigated whether rebalancing the maternal omega-6 to omega-3 fatty acid (n-6/n-3 FA) ratio during pregnancy and lactation could mitigate PTOA severity in adult offspring. METHODS: Wildtype (WT) and fat-1 female mice, which endogenously convert n-6 to n-3 PUFAs, were fed either a control or n-6-enriched HFD and mated to control-fed males. WT offspring were evaluated developmentally at embryonic day E17.5 and in adulthood for metabolic and musculoskeletal outcomes 12-weeks following destabilization of the medial meniscus (DMM) surgery. RESULTS: WT fetal offspring from fat-1 dams had increased circulating levels of the anti-inflammatory cytokine IL-4 and decreased levels of the inflammatory cytokine TNFα, indicating a less inflammatory systemic environment than offspring from WT dams. Fetal offspring of fat-1 dams also had increased bone volume and bone mineral density. When raised to adulthood, offspring displayed sexually dimorphic metabolic and musculoskeletal responses. Male offspring: Neither maternal diet nor genotype influenced whole body metabolism or cartilage damage following DMM in male offspring. Maternal HFD increased osteophyte severity and increased subchondral bone remodeling in the lateral tibial plateau. Maternal fat-1 genotype mitigated DMM-induced synovitis, but this change did not protect offspring from displaying pain-related behaviors. Female offspring: Maternal HFD increased body fat, cartilage damage, and synovitis following DMM surgery in offspring of WT dams. Maternal HFD also impaired trabecular bone properties at the tibial metaphysis in offspring of both WT and fat-1 dams. Maternal fat-1 genotype did not protect against structural changes in the knee joints following injury. However, female offspring of fat-1 dams were remarkably protected from displaying pain-related behaviors. Furthermore, decreasing the maternal n-6/n-3 FA ratio decoupled the correlation between synovitis and pain-related behaviors in female offspring from fat-1 dams. CONCLUSIONS: These findings suggest decreasing the maternal n-6/n-3 FA ratio mitigates OA-related pain behaviors in female offspring, with evidence of sex-specific differences in cartilage damage and pain. </p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13245099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interferon α-induced HERC6 provokes podocyte dysfunction via mitotic catastrophe in lupus nephritis.","authors":"Xiaoquan Wei, Shuhui Wang, Wenkun Peng, Yang Hang, Qianyue Yang, Shuning Sun, Defang Meng, Min Nie, Genhong Yao, Lingyun Sun","doi":"10.1186/s13075-026-03814-w","DOIUrl":"10.1186/s13075-026-03814-w","url":null,"abstract":"<p><p>BACKGROUND: HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase Family Member 6 (HERC6) is an IFN-stimulated gene (ISG) encoding an E3 ubiquitin ligase that plays significant roles in antiviral innate immunity. However, current research on HERC6 has primarily focused on the liver and immune cells. Its expression, regulation, and function in the kidney, particularly in podocytes remain largely unexplored. The aim of this study is to investigate the pathogenic role and mechanism of the E3 ubiquitin ligase HERC6 in podocyte injury of lupus nephritis (LN). METHODS: Key genes were identified through bioinformatic screening of LN patient datasets. HERC6 expression was validated in renal tissues from LN patients and two lupus murine models, and the correlation between its urinary HERC6 levels and the clinical parameters of patients was analyzed. In vivo, the therapeutic efficacy of renal HERC6 knockdown was evaluated in MRL/lpr mice using AAV9-mediated delivery of HERC6-specific shRNA.In vitro, podocytes were stimulated with IFN-α to investigate gene induction. Following HERC6 knockdown, cellular phenotypes, inflammatory cytokine secretion, apoptosis, cell cycle, and mitotic spindle morphology were analyzed using qPCR, western blot, flow cytometry, ELISA, and immunofluorescence. RESULTS: Bioinformatic analysis identified HERC6 as a key differentially expressed gene in LN. Its significant upregulation was validated in renal tissues especially in glomerulus from LN patients and two murine lupus models. Moreover, clinical specimen analysis verified significantly elevated urinary HERC6 levels in LN patients, which correlated tightly with disease activity indicators, including proteinuria and hypocomplementemia. Renal-targeted HERC6 knockdown significantly attenuated lupus nephritis progression in MRL/lpr mice, alleviated both LN progression and podocyte injury. Mechanistically, type I interferon (IFN-α) directly induced HERC6 expression in podocytes. Functional experiments demonstrated that HERC6 knockdown markedly alleviated IFN-α-induced podocyte injury, characterized by restoring expression of podocyte markers, reducing secretion of inflammatory cytokines and decreasing apoptosis. Further investigation revealed that HERC6 deficiency reversed IFN-α-induced mitotic spindle abnormalities and G2/M phase arrest. CONCLUSION: This study unveiled a novel pathway wherein HERC6 induced podocyte injury through disruption of mitotic homeostasis, revealed its potential as a therapeutic target in LN. </p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13235120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into axial spondyloarthritis features and the development of imaging evidence of sacroiliitis during long-term follow-up in routine clinical practice.","authors":"Stan Corné Kieskamp, Marjan Jolanda Nijmeijer, Fréke Wink, Reinhard Bos, Suzanne Arends, Anneke Spoorenberg","doi":"10.1186/s13075-026-03811-z","DOIUrl":"10.1186/s13075-026-03811-z","url":null,"abstract":"<p><p>OBJECTIVE: To analyse characteristics and SpA features of newly diagnosed patients with radiographic (r-) versus non-radiographic (nr-)axSpA, and nr-axSpA patients fulfilling the imaging versus clinical arm of the ASAS classification criteria. Furthermore, this study explored whether patients from the clinical arm developed imaging evidence of sacroiliitis during follow-up. METHODS: Consecutive newly diagnosed axSpA patients included in the prospective GLAS cohort between 2009 and 2019 were analysed. Demographic data and SpA features were compared between groups using multivariable logistic regression analysis. Patients fulfilling the clinical arm were evaluated for the development of radiographic sacroiliitis during follow-up. RESULTS: 305 patients with a recent axSpA diagnosis were included. Mean age was 38 ± 12 years, 55% were males, median diagnostic delay was 6 (IQR 2–13) years, and 75% were HLA-B27+. Patients diagnosed with r-axSpA (n = 170; 56%) were more often male and had more often elevated CRP than patients diagnosed with nr-axSpA. Patients with nr-axSpA had more often inflammatory back pain and a positive family history of SpA. Clinical diagnosis was made without imaging evidence of sacroiliitis in 38 (12%) patients. Only 2 (5%) of these patients later developed sacroiliitis on imaging (median follow-up 8 years). CONCLUSION: Overall, diagnosed and classified axSpA patients have similar clinical presentation and disease burden. In approximately 1 in 10 patients, axSpA diagnosis was made without imaging evidence of sacroiliitis, with a negligible number developing sacroiliitis on imaging during long-term follow-up. Imaging may improve diagnostic confidence, which can prevent reconsideration of the diagnosis and reduce inappropriate management decisions and expectations. </p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13245024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin G and plasma glycome in early rheumatoid arthritis differ from matched controls and link less fat-free mass to an accelerated aging phenotype: an exploratory study.","authors":"Sidra W Hashmi, Brian J Andonian, Mary M Thompson, William C Bennett, Alyssa M Sudnick, Johanna L Johnson, Leanna M Ross, Katherine A Collins-Bennett, Kelsey B Belski, Martina Vinicki, Tea Pribic, Gordan Lauc, Sridevi Krishnan, Kim M Huffman","doi":"10.1186/s13075-026-03818-6","DOIUrl":"10.1186/s13075-026-03818-6","url":null,"abstract":"<p><p>BACKGROUND: In patients with rheumatoid arthritis (RA), the immunoglobulin G (IgG) glycome is altered and characterized by decreased galactosylation. The goals of our exploratory study were to identify (1) alterations in the IgG and plasma glycome and GlycanAge—a glycome-based biological age measure—in patients with early RA and (2) changes in the RA glycome following a lifestyle intervention. METHODS: IgG and plasma glycome and clinical and physiological parameters were analyzed from two cohorts: (1) participants with early RA (symptom duration < 6 months; n = 10) and age-, sex- and BMI-matched healthy controls (n = 10); and (2) older participants (age > 60) with RA (n = 20) who completed a diet and exercise intervention. RESULTS: As compared to controls (chronologic age = 53.2 ± 12.3 years), early RA (chronologic age = 53.6 ± 12.9 years) had a GlycanAge corresponding to 18.1 years older (42.1 ± 25.3 versus 60.2 ± 19.5 years; p = 0.03), greater plasma tetra-galactosylated, tri-sialylated, tetra-sialylated, and antennary fucosylated glycans, and lesser plasma mono-sialylated and oligomannan glycans (p < 0.05 for all). Controlling for chronologic age and sex, RA (n = 39) GlycanAge was negatively associated with cardiorespiratory fitness (V̇O2 peak, mL/kg/min; beta=-1.66, p = 0.005) and fat-free mass (kg; beta=-1.77, p = 0.004). While a diet and exercise lifestyle intervention for RA (n = 20) did not significantly alter glycome parameters, reductions in GlycanAge were associated with increases in fat-free mass (Spearman rho=-0.46, p = 0.04). CONCLUSION: Changes in the RA glycome occur early in the RA disease process and may be useful as biomarkers for RA diagnosis and monitoring. Further study is needed to explore the potential for lifestyle interventions targeting improvements in cardiorespiratory fitness and body composition to impact the glycome and accelerated biological aging linked to RA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04226131, registered on January 13, 2020 NCT04356183, registered on April 22, 2020. </p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13227829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and safety outcomes of rheumatoid arthritis patients treated with AMGEVITA^® in the United Kingdom using data from a national register.","authors":"Argentina E Servin, Mark Lillie, Ran Jin, Laura C Coates, Michele Brunori, Latha Krishnamoorthy, Neil Accortt, Frances Humby","doi":"10.1186/s13075-026-03807-9","DOIUrl":"10.1186/s13075-026-03807-9","url":null,"abstract":"<p><p>BACKGROUND: Over the past decade, rheumatoid arthritis (RA) management in the UK has evolved with increased use of biologic and targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The introduction of biosimilars, including AMGEVITA®, has expanded treatment options and improved access for patients. This study aims to (1) describe the clinical characteristics and serious adverse events (SAEs) in RA patients treated with AMGEVITA®, and (2) similarly, describe the incidence of these outcomes from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) anti-tumor necrosis factor (anti-TNF) comparison cohort. METHODS: The BSRBR-RA is a national registry for patients with RA receiving biologic treatments, including anti-TNF inhibitors (e.g., adalimumab) and non-anti-TNF biologics, designed to evaluate the long-term safety and effectiveness of these agents in clinical practice. SAE analyses derived from an interim pharmacovigilance report on a subset of all AMGEVITA® and anti-TNF patients in the BSRBR-RA based on the Manchester Template Report. Eligible participants were ≥ 16 years of age with RA who registered in the registry within 6 months of initiating AMGEVITA®. Descriptive statistics were calculated for all variables of interest. RESULTS: From 01/01/2019 to 31/03/2022, 288 RA patients initiating AMGEVITA® were enrolled. Follow-up ended 30/11/2023. The mean (SD) age was 59.7 (12.0) years; 86 (28.0%) were male; and mean (SD) disease duration at initiation was 9.9 (9.8) years. Two-thirds of AMGEVITA® patients were biologically naïve and 9.8% were using steroids at initiation. The crude incidence rate of SAEs in the AMGEVITA® cohort was 9.6 per 1,000 patient-years (95% CI: 3.1–22.4), including 37.5 serious infections per 1,000 patient-years (95% CI: 95% CI: 23.2–57.3). For context, the anti-TNF comparator cohort had a crude SAE rate of 13.3 per 1,000 patient-years (95% CI: 10.6–16.5) and a serious infection rate of 49.1 per 1,000 patient-years (95% CI: 43.8–54.8). CONCLUSION: The crude incidence rates of SAEs and serious infections among AMGEVITA® users were within the range observed for the anti-TNF comparator cohort. These findings provide supportive real-world safety data, although differences in baseline characteristics and the absence of adjusted analyses should be considered when interpreting results. </p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13235186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}